北京市中伦律师事务所 关于华勤技术股份有限公司 第一个解除限售期解除限售条件成就、回购注销 部分限制性股票及调整回购价格的 | | | | | 法律意见书 二〇二五年六月 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 北京 • 上海 | • 深圳 | • 广州 | • 武汉 | • 成都 | • 重庆 | • 青岛 | • 杭 | | 州 | • 南京 • 海口 • 东京 | | • 香港 | • 伦敦 | • 纽约 | • 洛杉矶 | • 旧金 | | 山 | • 阿拉木图 | | | | | | | 致：华勤技术股份有限公司 根据华勤技术股份有限公司（以下简称"华勤技术"或"公司"）与北京市 中伦律师事务所（以下简称"本所"）签订的《专项法律服务合同》的约定及受 本所指派，本所律师作为公司 2023 年限制性股票激励计划（以下简称"激励计 划"或"本次激励计划"）相关事宜的专项法律顾问，就本次激励计划的首次授 予部分第一个解除限售期解除限售条件成就（以下简称"本次解除限售"）、回购 注销部分限制性股票（以下简称"本次回购注销"）及调 ...

Group 1 - The company held its fourth supervisory board meeting on June 20, 2025, with all three supervisors participating in the vote, confirming the legality and validity of the resolutions passed [1][2] - The supervisory board approved the grant of restricted stock to 72 eligible recipients at a price of 72.81 yuan per share, totaling 1,186,440 shares [1][2] Group 2 - The supervisory board also approved the use of part of the idle raised funds for cash management, which is expected to enhance the efficiency of fund utilization and generate investment returns without harming the interests of the company or minority shareholders [2] - The authorized period for this cash management is from August 4, 2025, to August 3, 2026, with a maximum amount not exceeding 12 months for rolling use [2]

Core Viewpoint - The legal opinion letter from Grandway Law Office confirms the compliance and legitimacy of Nanjing Lewei New Technology Co., Ltd.'s 2025 Restricted Stock Incentive Plan, ensuring it meets relevant laws and regulations [2][24]. Group 1: Legal Compliance - The law firm conducted thorough verification of the legal documents and facts related to the incentive plan, ensuring all findings are accurate and complete [2][3]. - Nanjing Lewei is a legally established and effectively existing company, having been listed on the Shenzhen Stock Exchange since June 30, 2021 [3][4]. Group 2: Incentive Plan Details - The incentive plan aims to attract and retain talent, aligning the interests of shareholders, the company, and the core team [22][23]. - The plan includes 1,000,000 restricted stocks to be granted to 34 individuals, with specific allocations for key personnel [10][11]. - The grant price for the restricted stocks is set at 8.55 RMB per share, which complies with legal requirements [15]. Group 3: Conditions and Procedures - The plan stipulates that the stocks will vest in two phases, with the first 50% vesting after 12 months and the remaining 50% after 24 months, contingent on performance metrics [12][16]. - The company must follow specific procedures for public disclosure and approval from the shareholders' meeting before implementing the plan [21][24]. - The incentive plan does not provide financial assistance to the recipients, ensuring compliance with regulatory standards [22][24].

Core Viewpoint - The company has completed the procedures for the third unlock period of the restricted stock incentive plan, allowing for the circulation of shares that were previously restricted [1][7]. Summary by Sections Incentive Plan Approval and Execution - The company has conducted the necessary approval procedures for the 2021 restricted stock incentive plan, including the review and approval of relevant proposals by the board and the supervisory committee [2][3]. - The initial grant of restricted stock involved 173 individuals, with a total of 1.6477 million shares granted, and the listing date for these shares was December 24, 2021 [2]. Unlocking Conditions and Performance Assessment - The third unlock period for the restricted stock is defined as the period from 42 months after the initial grant registration to the last trading day within 54 months from the grant date, allowing for 40% of the total granted shares to be unlocked [7]. - The company has confirmed that the conditions for unlocking the third period have been met, with 143 individuals eligible to unlock a total of 1,787,948 shares [7][18]. Changes in Share Structure - Following the unlocking of shares, the total number of shares with restrictions decreased from 77,083,531 to 75,295,583, while the total number of unrestricted shares increased from 151,904,648 to 153,692,596 [18]. - The total share capital of the company remains at 228,988,179 shares after the adjustments [18]. Adjustments to the Incentive Plan - The number of individuals participating in the incentive plan has been adjusted due to personal reasons leading to the forfeiture of shares by some participants, resulting in a reduction of the total granted shares [14][15]. - The company has also conducted buybacks of restricted shares from individuals who no longer qualify for the incentive plan due to leaving the company [5][16].

Core Viewpoint - The legal opinion letter confirms that SANY Heavy Industry Co., Ltd. has met the necessary conditions for the second release of restrictions on its stock incentive plan, in compliance with relevant laws and regulations [1][14]. Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the second release of restrictions on its stock incentive plan, as outlined in the relevant proposals [8][14]. - Related directors recused themselves from voting on the proposals, and independent directors expressed their agreement [8][14]. Group 2: Specifics of the Release of Restrictions - The second release period for the restricted stock is defined as starting from the first trading day after 32 months from the initial grant date until the last trading day within 44 months, allowing for a release of 50% of the total granted restricted stock [8][12]. - The company granted a total of 22,386,250 restricted shares to 126 incentive recipients, with 10,174,200 shares eligible for release, representing 0.12% of the company's total shares [6][12]. - The performance assessment for the second release period requires the company to achieve either a 20% increase in revenue or net profit compared to 2022, with a target net profit of 5.975 billion [12][14]. Group 3: Compliance with Conditions - The company has not encountered any disqualifying events that would prevent the release of restrictions, such as negative audit opinions or violations of profit distribution regulations [9][10]. - The incentive recipients have also not been disqualified by regulatory bodies within the past 12 months [9][10].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 调整公司 2025 年限制性股票激励计划授予价格：22.78 元/股调整为 22.62 元 /股 证券代码：688621 证券简称：阳光诺和 公告编号：2025-055 北京阳光诺和药物研究股份有限公司 关于调整公司 2025 年限制性股票激励计划授予价格 的公告 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺和"）于 第六次会议审议通过了《关于调整公司 2025 年限制性股票激励计划授予价格的 议案》等议案。鉴于公司已于 2025 年 6 月 11 日实施完毕 2024 年年度权益分派， 根据《2025 年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"） 的规定及公司 2025 年第二次临时股东会的授权，对公司 2025 年限制性股票激励 计划（以下简称"本次激励计划"或"激励计划"）的 2025 年限制性股票激励计划 授予价格进行调整。授予价格（含预留部分）由 22.78 元/股调整为 22.62 元/股。 现将有关事项说 ...

Core Viewpoint - 科恒股份 has experienced significant stock price fluctuations, with a notable increase of 20.92% this week, reaching a closing price of 15.84 yuan as of June 13, 2025, and hitting a nearly one-year high of 20.85 yuan during intraday trading on June 11, 2025 [1][3]. Trading Information Summary - The stock price of 科恒股份 showed an abnormal fluctuation, with a cumulative price increase deviation of 43.55% over two consecutive trading days (June 9 and June 10, 2025), which is classified as an abnormal trading situation according to Shenzhen Stock Exchange regulations [3][11]. - The stock has also appeared multiple times on the "龙虎榜" due to a daily turnover rate of 30% and a daily increase of 15% [3]. Company Announcements Summary - The sixth board meeting of 科恒股份 approved several key proposals, including: - Initiating commodity futures hedging business with a maximum margin of 50 million yuan, effective for twelve months [4][8]. - Providing external guarantees for financing up to 11.4 million yuan from the controlling shareholder, Zhuhai Gree Financial Investment Management Co., Ltd. [4][8]. - Canceling 1.7834 million stock options that have been granted but not exercised [4][9]. - Repurchasing and canceling 378,650 restricted stocks with a total repurchase amount of approximately 2.91 million yuan [4][10]. - Reducing registered capital and amending the company’s articles of association [4]. - Calling for a temporary shareholders' meeting on June 26, 2025, to review these proposals [6]. Monitoring Committee Review - The monitoring committee confirmed the accuracy of the stock option cancellations and the repurchase of restricted stocks, stating that these actions comply with relevant regulations and will not significantly impact the company's operating performance [5].

Core Viewpoint - The legal opinion letter from Shanghai Junlan Law Firm confirms that Beijing Bairen Medical Technology Co., Ltd.'s stock incentive plan adjustments, including vesting, cancellation, and price adjustments, comply with relevant regulations and have received necessary approvals [1][19]. Group 1: Approval and Authorization - The board of directors approved the proposals related to the 2020 Restricted Stock Incentive Plan, including the fifth vesting period for the initial grant and the third vesting period for reserved grants [4][5]. - The necessary approvals and authorizations for the vesting, cancellation, and adjustment have been obtained as of the date of the legal opinion letter [4][19]. Group 2: Vesting, Cancellation, and Adjustment Details - The fifth vesting period for the initial grant is set from July 17, 2025, to July 16, 2026, while the third vesting period for reserved grants is from July 15, 2025, to July 14, 2026 [6][18]. - A total of 65 incentive objects are eligible for the fifth vesting period, with 57 rated as A, allowing for 100% vesting [9][13]. - The company will cancel 0.7504 million shares of unvested restricted stock due to two incentive objects leaving the company [12][16]. - The adjusted grant price for the incentive plan is set at 15.11 yuan per share after accounting for cash dividends [17][19]. Group 3: Performance Assessment - The company's 2024 revenue target is set at 439 million yuan, with a trigger value for performance assessment [8][10]. - The company achieved a revenue of 370.6383 million yuan in 2023, reaching 88.25% of the target value [10][14]. - The performance assessment for the incentive objects will determine the actual number of shares vested based on company and individual performance metrics [15][16]. Group 4: Information Disclosure - The company is required to disclose relevant information regarding the incentive plan adjustments in accordance with regulatory requirements [18][19]. - The legal opinion confirms that the company has fulfilled its current information disclosure obligations and will continue to do so [19].

证券代码：603203 证券简称：快克智能 上海荣正企业咨询服务（集团）股份有限公司 关于 快克智能装备股份有限公司 调整及首次授予事项 之 独立财务顾问报告 目 录 一、释义 本独立财务顾问报告中，除非文义载明，下列简称具有如下含义： 简称 释义 快克智能、本公司、 指 快克智能装备股份有限公司 公司、上市公司 本激励计划 指 快克智能装备股份有限公司 2025 年限制性股票激励计划 独立财务顾问 指 上海荣正企业咨询服务（集团）股份有限公司 《上海荣正企业咨询服务（集团）股份有限公司关于快克智能 独立财务顾问报告 指 装备股份有限公司 2025 年限制性股票激励计划调整及首次授予 事项之独立财务顾问报告》 公司根据本激励计划规定的条件和价格，授予激励对象一定数 限制性股票 指 量的公司股票，该等股票设置一定期限的限售期，在达到本激 励计划规定的解除限售条件后，方可解除限售流通 按照本激励计划规定，获得限制性股票的公司董事（不含独立 激励对象 指 董事）、高级管理人员、公司及子公司的核心技术、业务骨干及 其他核心骨干人员 授予日 指 公司向激励对象授予限制性股票的日期，授予日必须为交易日 授予价格 指 公司 ...

方正科技集团股份有限公司监事会 根据《公司法》 《证券法》 《上海证券交易所股票上市规则》和《上市公司股 权激励管理办法》等相关法律、法规以及《公司章程》的有关规定，方正科技集 团股份有限公司（以下简称"公司"）监事会审阅了公司《2025 年限制性股票 激励计划（草案）》及其相关资料，核查意见如下： 一、监事会对公司《2025 年限制性股票激励计划（草案）》及其摘要的核查 意见 监事会认为：公司《2025 年限制性股票激励计划（草案）》及其摘要的内容 符合《公司法》《证券法》《上市公司股权激励管理办法》《转发国务院国资委关 于中央企业控股上市公司实施股权激励工作指引的通知》 关于公司 2025 年限制性股票激励计划相关事项 的核查意见 号）等相关法律、法规和规范性文件的规定。本次激励计划的实施将有利于公司 进一步建立健全中长期激励约束机制、强化正向激励导向作用，促进公司高质量、 可持续发展，不存在损害公司及全体股东利益的情形。 二、监事会对公司《2025 年限制性股票激励计划实施考核管理办法》的核 查意见 监事会认为：公司《2025 年限制性股票激励计划实施考核管理办法》旨在 保证公司 2025 年限制性股票 ...